Double-blind comparison of etodolac and diclofenac in patients with rheumatoid arthritis.

The efficacy and tolerability of etodolac was compared to diclofenac in a multi-centre, double-blind, randomized parallel group study. Fifty-three patients with rheumatoid arthritis received etodolac (400 mg/day) and 55 patients received diclofenac (150 mg/day) for 12 weeks. Thirty-nine etodolac-treated patients and 44 diclofenac-treated patients completed the study.

[Therapy study of chronic polyarthritis with sulfasalazine with special emphasis on the profile of side effects].

138 patients, suffering from rheumatoid arthritis, were treated with sulfasalazine for up to 43 months. In 58.7% of the patients a good or moderate effect was ascertained.

[Lonazolac-Ca-a non-steroidal antirheumatic agent. Long-term clinical study in chronic polyarthritis].

During a controlled open long-term study, Lonazolac-Ca, a new nonsteroidal antiphlogistic substance, has been tested in 35 patients with rheumatoid arthritis (stage I-III, according to Steinbrocker). The patients took 600 mg Lonazolac-Ca daily in three equal doses. The observation period was one year.